STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D

Cardiovascular Therapeutics

Volumn 29, Issue 2, 2011, Pages 146-152

  Ertugrul, Derun Taner ^a   Yavuz, Bunyamin ^a   Cil, Hicran ^a   Ata, Naim ^a   Akin, Kadir Okhan ^a   Kucukazman, Metin ^a   Yalcin, Ahmet Arif ^a   Dal, Kursad ^a   Yavuz, Burcu Balam ^b   Tutal, Emre ^a  

^a Kecioren Teaching and Research Hospital ^*  (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

25 Hydroxyvitamin D; Fluvastatin; Rosuvastatin; Statin

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; 25-HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN D METABOLISM; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ALKALINE PHOSPHATASE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; VITAMIN D;

EID: 79952021197     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00141.x     Document Type: Article

References (24)

1. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344:1383-1389.
3. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4-12.
4. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008;168:1174-1180.
5. Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med 1996;89:579-589.
6. Mortimer EA, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N Engl J Med 1977;296:581-585.
7. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-761.
8. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-1209.
9. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1, 25-dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009;23:295-299.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). J Am Med Assoc 2001;285:2486-2497.
11. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-1637.
12. Grimes DS. Are statins analogues of vitamin D? Lancet 2006;368:83-86.
13. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Dueñas A. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-905.
14. Wilczek H, Sobra J, Justová V, et al. Iatropathogenic effect of Mevacor on vitamin D metabolism. Cas Lek Cesk 1989;128:1254-1256.
15. Wilczek H, Sobra J, Ceska R, Justová V, Jůzová Z, Procházková R, Kvasilová M. Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia. Cas Lek Cesk 1994;133:727-729.
16. Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: A meta-analysis. Osteoporos Int 2005;16:990-998.
17. Staal A, Frith JC, French MH, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003;18:88-96.
18. Edwards JE, Moore RA. Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003;4:18.
19. Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int 2005;16:1272-1276.
20. Bjarnason NH, Riis BJ, Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 2001;12:380-384.
21. Galus R, Włodarski P, Włodarski KH. Fluvastatin does not elevate periosteal osteogenesis induce by Moloney sarcoma virus (MSV) in mice. Pharmacol Rep 2006;58:60-66.
22. Hughes A, Rogers MJ, Idris AI, Crockett JC. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 2007;81:403-413.
23. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha, 25-dihydroxyvitamin D(3): Implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56-65.
24. Frishman WH, Horn J. Statin-drug interactions: Not a class effect. Cardiol Rev 2008;16:205-212.